Q1FY22 Result Update | IT

Momentum revived

DALAL & BROACHA

Equity Research Desk

July 15, 2021

Infosys' Q1FY22 performance was a mixed bag with revenue beating our estimates and revenue growth guidance for FY22 increased whereas profitability was below our estimates

- \$ Revenue came in at \$3,782 Mn, +4.7% qoq / +18.3% yoy and +0.5% above estimates
- INR revenue came in at INR 2,78,960 Mn, +6% gog / +17.9% yoy and 0.5% above our estimates
- Digital Revenues grew 9.7% qoq / 46.9% yoy
- **EBIT** was reported at INR 66,030 Mn, +2.5% gog / +23.1% yoy and -2.4% vs our estimates
- **EBIT margins stood at 23.7%**, vs 24.5% / 22.7% in Q4FY21 / Q1FY21 respectively and 70 bps below our estimates
- **PAT came in at INR 51,950 Mn,** +2.3% gog / +24.1% yoy and -3.2% below our estimates
- EPS at INR 12.24 in Q1FY22 vs 12 / 9.8 in Q4FY21 / Q1FY22 respectively

Segmental Trends

Growth across the verticals was led by

- BFSI (33% of topline) which grew by 27% YoY followed by Source: Bloomberg Retail (15% of topline) growing at 26.6% YoY, Lifesciences (6.8% of Revenue) growing at 23.4% YoY and Manufacturing (9.7% of topline) growing at 23.1% YoY on reported basis.
- Hi-Tech (8.3% of topline) grew by 15.1% YoY followed by Energy & Utilities (12.1% of topline) growing at 14.5% YoY and Communications (12.2% of topline) that grew at 10.6% Source: BSE YoY on reported basis. Others (2.9% of topline) also grew by 16.3% YoY on reported basis.

Rating	TP (Rs)	Up/Dn (%)
HOLD	1591	1
Market data		
Current price	Rs	1577
Market Cap (Rs.Bn)	(Rs Bn)	6719
Market Cap (US\$ Mn)	(US\$ Mn)	90224
Face Value	Rs	5
52 Weeks High/Low	Rs	1591/781
Average Daily Volume	('000)	4628
BSE Code		500209
Bloomberg		INFY:IN
Source: Bloomberg		

One Year P	erforman	ce		
215 7				
195 -				بهمار
175 -		M =	m	~
155 -		يامها الريد	J	
135 -			Mynner	
115 -	مرسد	•		
95	Ψ			
Jul-20	Oct-20	Jan-21	Apr-21	Jul-21
	— Infosys	-	Nift	у

% Shareholding	Mar-21	Dec-20
Promoters	12.95	12.95
Public	86.69	86.69
Others	0.36	0.36
Total	100	100

I	Fi	na	nc	ia	l Sı	ımı	ma	rv/
ı	ГΙ	на	IIL	ıa	ı JL	41 I I I I	на	ıν

· ····aiiciai baiiiiai y					
Y/E Mar (Rs mn)	FY 19	FY 20	FY 21	FY 22E	FY23E
Net sales	8,26,760	9,07,910	10,05,531	11,54,062	13,06,831
EBIT	1,88,790	1,93,740	2,47,021	2,73,777	3,09,523
Adjusted net profit	1,61,310	1,66,400	1,94,551	2,16,789	2,51,512
Free cash flow	1,47,130	1,43,925	1,62,996	1,45,007	2,04,964
EPS (Rs)	37.1	38.3	44.8	49.9	57.9
growth (%)	0%	3%	17%	11%	16%
P/E (x)	42.5	41.2	35.2	31.6	27.3
P/B (x)	10.6	10.5	9.4	8.4	7.5
EV/EBITDA (x)	35.3	34.5	27.0	24.3	21.3
ROCE (%)	22.2	22.8	24.1	24.2	25.0
RoE (%)	22.5	23.8	25.9	25.8	26.6
Dividend vield (%)	1.6	1.1	1.4	1.6	1.8

Source: Dalal & Broacha Research

Mayank Babla (022) 67141412 mayank.babla@dalal-broacha.com

Timshar Dhamodiwala (022) 67141441 timshar.dhamodiwala@dalal-broacha.com

Geographical Trends

Growth was primarily led by India (2.9% of Revenue) growing at 23.1% YoY on reported basis, followed by Europe (24.2% of Revenue) having a healthy growth of 21.9% YoY on reported basis. North America (61.7% of Revenue) had a robust growth of 21.6% YoY on reported basis. Rest of the World (11.2% of Revenue) grew by 16.9% YoY on reported basis.

Conference Call Key Highlights

Operational Highlights

- Landmark year with a robust growth of 16.9% YoY & 4.8% QoQ in cc terms which has been the fastest growth witnessed in the industry over the decade.
- Digital Business (53.9% of Overall Revenue) grew by 42%
 YoY
- DSO improved by 1 day to 70 on the back of robust collections.
- Free Cash Flow remained robust at \$863 Mn growing by 18.5%
 YoY. FCF Conversion stood at 122% of net profit.
- Cash & Investment stood at \$5.07 Bn after returning approximately \$1 Bn of final dividend and buyback.
- Onboarded 10,000 college graduates in Q1FY22.
- Utilization improved to an all-time high of 88.5%. Onsite efforts mix reduced to 24.1%
- Sub-con costs increased by 120 bps due to stronger growth than expectations, higher attrition and demand for niche skills.

Vertical Performance Highlights

- BFSI: Growth performance in the financial services continued with steady increase in the growth momentum aided by signings during the quarter. Growth is led by sub-segments like Banking, Mortgages, Wealth Services. Demand for cloud adoption has increased substantially and the firm is making efforts to employ cloud migration, cloud management and other cloud related activities.
- Retail: Performance of the retail segment improved with new deal signings as well as ramp up of previous deal wins. There have been aggressive investments by clients to uplift their digital capabilities. Investment in analytics across supply chain, freight promotion improvement, etc.
- Communication: Improvement in performance was led by new deal signings and ramp up of previous deal wins. The need for better connectivity has led to deployment of 5G services.
- Energy & Utilities: Grew string double-digit along with deal wins during the quarter. Overall improvement in outlook across sub-sectors and geographic outlay.
- Manufacturing: Strong growth in manufacturing led by deal wins in the past quarters. Increased spending in areas of

Operating Margin was 23.7% improving by 100 bps YoY and declined by 80 bps QoQ basis. Improvement was due to 10 bps benefits from currency movements, 40 bps due to increase in utilization which was offset by 50 bps due to sub-con and third-party costs and additional 80 bps due to costs related to employee hiring and promotions.

Net Head Count increased by 8300 people. Attrition for the quarter inched up to 13.9% for Q1 vs 10.9% in Q4FY21 and 15.6% in O1FY21.

Growth was broad-based with all the industries posting double-digit growth including financial services and retail growing more than 20% YoY.

15 July 2021 | 2 |

Digital such as Industrial IoT, cloud adoption, etc. will make the manufacturing value chain to be smarter and faster.

 Healthcare: Strong double-digit growth led by new offerings such as supply nourishing solutions for complex, digital health platforms for patient engagement helps in accelerating digital options to pharma industry.

Deal Wins & Pipeline

- Large deal signings stood at \$2.6 Bn in Q1FY22 vs \$2.1 Bn /
 \$1.8 Bn in Q4FY21 / Q1FY21 respectively
- Vertical Deal Wins: BFSI 9 Deals, Retail 4, Lifesciences 1 Deal, Communication 1 Deal, Hi-Tech 1 Deal, Manufacturing 3 Deals, Energy & Utilities 4 Deals each vertical.
- Geographical Deal Wins: America 14 Deals, Europe 5
 Deals, India 1 Deal & Rest of World 2 Deals.
- Expect Daimler deal to start ramping up going ahead.

Share Buyback

 Initiated share buyback on May 25. Maximum buyback size of INR 9,200 Crores. Till 30th, completed INR 690 Crores that is 7.5% of the buyback by the end of Q1FY22.

Outlook & Guidance

- With a view of strong start to financial year with strong deal signing and robust pipeline, Management increased its FY22e revenue growth guidance from 12-14% cc to 14-16% cc growth.
- EBIT Margin guidance remains unchanged at 22-24% for FY22e.
- Attrition will be high in the near term due to strong demand.
- FY21 college graduate hiring target has been increased to 35,000 globally.

Won 22 Large deals in Q1FY22 totaling to \$2.6 Bn. Share of new deals was 30%.

Bought back 4.4 million shares at an average price of INR 1572. Till date completed INR 1542 Crores of share buyback and bought back 9.8 million shares at an average price of INR 1569.

Expecting discretionary costs to start normalizing in the upcoming quarter including travel facilities, etc. Compensation hikes will also be rolled out in Q2 to the majority of the employees.

15 July 2021 | 3 |

Quarterly Performance Analysis

Exhibit 1

YE March (Rs. Mn)	Q1 FY 22	Q4 FY 21	Q-o-Q change %	Q1 FY21	Y-o-Y change %	Q4 FY21 Est.	Deviation %
Net Sales (US\$ Mn)	3,782	3,613	4.7%	3,197	18.3%	3,763	0.5%
Net Sales (INR Mn)	2,78,960	2,63,110	6.0%	2,36,650	17.9%	2,77,562	0.5%
Less:							
Employees Remuneration & Benefits	1,85,060	1,71,640	7.8%	1,57,030	17.9%	1,79,358	3.2%
Administrative & Other Expenses	27,870	27,070	3.0%	25,970	7.3%	30,532	(8.7%)
Total Operating Expenditure	2,12,930	1,98,710	7.2%	1,83,000	16.4%	2,09,890	1.4%
EBIT	66,030	64,400	2.5%	53,650	23.1%	67,672	(2.4%)
Less: Depreciation	8,290	8,310	(0.2%)	7,560	9.7%	8,766	
Add: Other income	5,730	4,950	15.8%	4,270	34.2%	6,245	(8.2%)
Finance Costs	0	0		480		425	
Profit Before Tax	71,760	69,350	3.5%	57,440	24.9%	73,492	(2.4%)
Adjusted Profits	71,760	69,350	3.5%	57,440	24.9%	73,492	
Less: Total Tax	19,750	18,570	6.4%	15,200	29.9%	19,843	
Minority Interest	60	20		390		0	
PAT	51,950	50,760	2.3%	41,850	24.1%	53,649	(3.2%)
Adjusted PAT	51,950	50,760	2.3%	41,850	24.1%	53,649	(3.2%)
Reported Diluted EPS (Rs.)	12.2	12.0	2.3%	9.8	24.4%	12.6	
Adjusted Diluted EPS (Rs.)	12.2	12.0	2.3%	9.8	24.4%	12.6	(3.2%)
No of Shared Diluted (mn)	4,249	4,246		4,259		4,249	
Margin Analysis %			Change		Change		Deviation
<i>3</i> ,	22 =4		in bps		in bps		in bps
EBIT Margin	23.7%	24.5%	(81)	22.7%	100	24.4%	(71)
EBIDTA Margin	26.6%	27.6%	(99)	25.9%	78	27.5%	(90)
NPM	18.6%	19.3%	(67)	17.7%	94	19.3%	(71)
Adjusted NPM Effective Tax Rate %	18.6%	19.3%	(<i>67</i>) 75	17.7% 26.5%	<i>94</i> 106	19.3%	(71) 52
checuve rax kate %	27.5%	26.8%		20.5%		27.0%	Deviation
Cost Analysis %			Change in bps		Change in bps		in bps
Employee Cost/Net Sales	66.3%	65.2%	110	66.4%	(2)	64.6%	1172
SG&A/Net sales	10.0%	10.3%	(30)	11.0%	(98)	11.0%	(101)

Source: Dalal & Broacha Research, Company

Valuation & Outlook

Infosys is currently trading at 31.6x / 27.3x FY22e/FY23e EPS respectively. The company delivered strong revenue growth which was above our expectations whereas margins were below our estimates mainly due to containing the attrition. Revenue growth guidance has been increased from 12-14% to 14-16% - which was largely expected by the street. Margin guidance has been retained at 22-24% owing to the fact that a wage hike will occur in Q2FY22 and certain post-COVID costs are expected to return from Q3FY22 onwards. Infosys has rallied over 16% over the last 3 months whereas TCS has rallied only 4% over the same period. Therefore, the valuation gap between Infosys and TCS has narrowed to low single digits. We expect that this gap will continue to remain albeit at low single digits. Taking the above factors into consideration, we believe that Infosys is at fair value at current levels. We maintain our HOLD rating on the stock with a revised target price of INR 1,591 (earlier 1,458).

15 July 2021 | 4 |

Financials

	Dı	rofit & Loss	Δ/c			
YEMarch (INR Mn)	FY 19	FY 20	FY21	FY 22E	FY23E	YE M
Net Sales	8,26,760	9,07,910	10,05,531	11,54,062	1 3,06,831	Liabi
Growth%	17.2%	9.8%	10.8%	14.8%	13.2%	Equity
Total Revenue	8,26,760	9,07,910	10,05,531	11,54,062	13,06,831	Rese
Less:						Equit
Employees Cost	5,38,680	6,07,320	6,54,150	7,61,820	8,40,539	Net \
SG&A	99,290	1,06,850	1,04,360	1,18,464	1,56,769	Net D
Operating Expenditure		7,14,170	7,58,510	8,80,285	9,97,308	Tota
EBITDA	2,08,890	2,22,670	2,85,331	3,08,073	3,48,359	Lease
EBITDA Growth%	9.9%	6.6%	28.1%	8.0%	13.1%	Capit Asset
Less: Depreciation	20,100	28,930	38,310	34,296	38,836	Gross
EBIT Growth%	1,88,790 10.1%	1, 93,740 2.6%	2,47,021 27.5%	2,73,777 10.8%	3,09,523 13.1%	Less:
Non-operating Income	28,830	28,030	21,030	24,982	32,671	Net E
Profit Before tax	2,17,620	2,20,080	2,66,601	2,97,484	3,42,194	Right
Tax	56,310	53,680	72,050	80,696	90,681	Capit
Net Profit	1,61,310	1,66,400	1,94,551	2,16,789	2,51,512	Inves
Adjusted Profit	1,61,310	1,66,400	1,94,551	2,16,789	2,51,512	Othe
Diluted EPSRs	37.1	38.3	44.8	49.9	57.9	Curre
Growth %	0.3%	3.2%	16.9%	11.4%	16.0%	Sund
Adjusted EPS	37.1	38.3	44.8	49.9	57.9	Cash
Growth%	0.3%	3.2%	16.9%	11.4%	16.0%	Loans
						Tota
		Key Ratio	s			Less:
YE March (Rs.mn)	FY 19	FY 20	FY21	FY 22E	FY 23E	Sund
EBITDA Margin(%)	25.3%	24.5%	28.4%	26.7%	26.7%	Provi
Tax/PBT(%)	25.9%	24.4%	27.0%	27.1%	26.5%	Othe
Net Profit Margin(%)	19.5%	18.3%	19.3%	18.8%	19.2%	Tota
RoE(%)	22.5%	23.8%	25.9%	25.8%	26.6%	Capi
RoCE(%)	22.2%	22.8%	24.1%	24.2%	25.0%	
Current Ratio(x)	2.8x	2.6x	2.8x	3.1x	3.2x	YEMar
Dividend Payout(%)	85.0%	57.2%	60.0%	60.0%	60.0%	
Book Value Per Share(Rs.)	149.4	150.6	168.5	188.4	211.6	EBITD/
Growth Indicators%						FC Inv
Growth in Gross Block(%)	13.4%	12.0%	11.7%	10.5%	9.5%	WC Ch
Sales Growth(%)	17.2%	9.8%	10.8%	14.8%	13.2%	Depre
EBITDA Growth(%)	10.1%	2.6%	27.5%	10.8%	13.1%	Tax (E
Net Profit Growth(%)	0.2%	3.2%	16.9%	11.4%	16.0%	FCFF
Diluted EPS Growth(%)	0.3%	3.2%	16.9%	11.4%	16.0%	
Turnover Ratios						
Debtors (Days of net sales	65	74	65	65	65	_
		Key Ratio	s			
EBIT Margin(%)	22.8%	21.3%	24.6%	23.7%	23.7%	
NPM(%)	19.5%	18.3%	19.3%	18.8%	19.2%	
RoE(%)	22.5%	23.8%	25.9%	25.8%	26.6%	
RoCE(%)	22.2%	22.8%	24.1%	24.2%	25.0%	
BV/PerShareRs.	149	151	168	188	212	
	V	aluation Ra	tios			
YE March (Rs.mn)	FY 19	FY 20	FY21	FY 22E	FY 23E	_
P/E(x)	42.5x	41.2x	35.2x	31.6x	27.3x	
P/BV(x)	10.6x	10.5x	9.4x	8.4x	7.5x	
EV/EBIDTA(x)	35.3x	34.5x	27.0x	24.3x	21.3x	
MarketCap./Sales(x)	8.3x	7.6x	6.8x	5.9x	5.2x	
			-			_

YE March (INR Mn)	FY 19	FY 20	FY21	FY 22E	FY23E
Liabilities					
Equity Capital	21,700	21,220	21,220	21,220	21,220
Reserves & Surplus	6,27,780	6,33,280	7,11,100	7,97,816	8,98,421
Equity	6,49,480	6,54,500	7,32,320	8,19,036	9,19,641
Net Worth	6,49,480	6,54,500	7,32,320	8,19,036	9,19,641
Net Deferred tax liability/	6,720	9,680	9,680	9,680	9,680
Total Loans	4,220	10,860	10,860	10,860	10,860
Lease Liabilities		40,140	40,140	40,140	40,140
Capital Employed	6,60,420	7,15,180	7,93,000	8,79,716	9,80,321
Assets					
Gross Block	2,28,910	2,56,410	2,86,410	3,16,410	3,46,410
Less: Depreciation	1,14,120	1,32,060	1,70,370	2,04,666	2,43,502
Net Block	1,14,790	1,24,350	1,16,040	1,11,744	1,02,908
Right of Use Assets		41,680	44,010	43,263	43,263
Capital WIP	56,190	81,400	86,943	89,171	91,462
Investments	49,650	48,950	48,950	48,950	48,950
Others-Assets	97,970	85,540	1,14,813	1,28,590	1,44,502
Current Assets					
Sundry Debtors	1,48,270	1,84,870	1,79,067	2,05,518	2,32,723
Cash and Bank Balance	1,95,100	1,82,550	2,05,958	2,22,910	2,82,776
Loans and Advances	57,460	56,960	80,442	98,095	1,11,081
Total Current Assets	5,28,200	5,41,820	5,96,187	6,76,551	7,96,468
Less: Current Liabilities					
Sundry Creditors	16,550	28,520	24,937	28,941	32,788
Provisions	21,430	20,620	27,676	30,997	34,833
Other Current Liabilities	1,48,400	1,59,420	1,61,328	1,58,615	1,79,612
Total Current Liabilitie		2,08,560	2,13,942	2,18,554	2,47,234
Capital Applied	6,60,420	7,15,180	7,93,000	8,79,716	9,80,321
		l = 1			
		sh Flow Sta			
YEMarch (INR Mn)	FY 19	FY20	FY21	FY 22E	FY 23E
EBITDA	2,08,890	2,22,670	2,85,331	3,08,073	3,48,359
FC Investment	27,120	27,500	30,000	30,000	30,000
WC Changes	14,210	(3,990)	(25,577)	(58,801)	(31,371)
Depreciation Tax Shield	5,201	7,056	10,353	9,303	10,291
Tax (EBITDA * Tax Rate)	54,051	54,312	77,112	83,568	92,315
		- ,			

1,47,130 1,43,925

1,62,996 1,45,007 2,04,964

Balance Sheet

Source: Dalal & Broacha Research, Company

15 July 2021 | 5 |

Disclaimer

Dalal & Broacha Stock Broking Pvt Ltd, hereinafter referred to as D&B (CINU67120MH1997PTC111186) was established in 1997 and is an integrated financial services player offering an extensive range of financial solutions and services to a wide spectrum of customers with varied needs ranging from equities to mutual funds to depository services. D&B is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE). D&B along with its affiliates offers the most comprehensive avenues for investments and is engaged in the securities businesses including stock broking (Institutional and retail), depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of a ssociates are available on our website i.e. www.dalal-broacha.com

D&B is registered as Research Analyst with SEBI bearing registration Number INH000001246 as per SEBI (Research Analysts) Regulations, 2014.

D&B hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in any time in the past. It has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time. SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on D&B for certain operational deviations in routine course of business.

D&B offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by D&B (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

D&B or its associates may have financial interest in the subject company.

D&B or its associates do not have any material conflict of interest in the subject company.

The Research Analyst or Research Entity (D&B) has not been engaged in market making activity for the subject company.

D&B or its associates may have a ctual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report.

Disclosures in respect of Research Analyst:

Whether Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report:	No
Whether the Research Analyst or his/her relative's financial interest in the subject company.	No
Whether the research Analyst has served a sofficer, director or employee of the subject company	No
Whether the Research Analyst has received any compensation from the subject company in the past twelve months	No
Whether the Research Analyst has managed or co-managed public of fering of securities for the subject company in the past twelve months	No
Whether the Research Analyst has received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
Whether the Research Analyst has received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
Whether the Research Analyst has received any compensation or other benefits from the subject company or third party in connection with the research report	No

D&B and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

15 July 2021 [6 |

In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, a vaila bility or use would be contrary to law or regulation or which would subject D&B or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to D&B. None of the material, nor its content, nor any

copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of D&B . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of D&B or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Name	Designation	Email	Phone	Sector
Mr. Kunal Bhatia	Head of Research	kunal.bhatia@dalal-broacha.com	022 67141442	Auto Auto Ancillary FMCG
Mrs.Charulata Gaidhani	Sr. Analyst	charulata.gaidhani@dalal-broacha.com	022 67141446	Pharma Healthcare
Mr. Mayank Babla	Sr. Analyst	mayank.babla@dalal-broacha.com_	022 67141412	IT Telecom Media
Mr. Avinash Tanawade	Sr. Analyst	avinash.tanawade@dalal-broacha.com_	022 67141449	BFSI
Mr. Akshay Ashok	Analyst	akshay.ashok@dalal-broacha.com_	022 67141486	BFSI
Mr. Miraj Shah	Associate	miraj.shah@dalal-broacha.com	022 67141489	FMCG Retail
Ms. Timshar Dhamodiwala	Associate	timshar.dhamodiwala@dalal-broacha.com	022 67141441	IT Telecom Media

Address: -508, Maker Chambers V, 221 Nariman Point, Mumbai 400021.

Tel: 91-22-2282 2992, 2287 6173, Fax: 91-22-2287 0092

E-mail: equity.research@dalal-broacha.com

15 July 2021 | 7 |